BiotechTube
Home/Inhibikase Therapeutics/Chris Cabell
CC

Chris Cabell

President, Head of Research & Development, Chief Medical Officer

Inhibikase Therapeutics

Therapeutic Areas

Cardiopulmonary DiseasePulmonary Arterial Hypertension

Inhibikase Therapeutics Pipeline

DrugIndicationPhase
IkT-001Pulmonary Arterial Hypertension (PAH)Phase 2

Leadership Team at Inhibikase Therapeutics

MI
Mark Iwicki
Chief Executive Officer
DM
David McIntyre
Chief Financial Officer
JA
John Adams
Chief Scientific Officer
VA
Vince Aurentz
Director
RB
Roberto Bellini
Director
DB
Dennis Berman
Director
DC
David Canner
Director
View full Inhibikase Therapeutics profile